[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Webmail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 28, Issue 4 (winter 2018) ::
MEDICAL SCIENCES 2018, 28(4): 283-289 Back to browse issues page
Quantitative investigation of BRIP1 and PALB2 expression level in Iranian women with breast cancer compared to normal samples
Elmira Shafiee1 , Ardeshir Hesampour 2
1- Graduate Student,Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran
2- Department of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran , a.hesampour@gmail.com
Abstract:   (3434 Views)
Background: Breast Cancer is the most common cancer in the world and it is the second reason of death between women following the lung cancer. The aim of this study was quantitative evaluation of BRIP1 and PALB2 genes expression level in blood samples of breast cancer comparing with normal people to investigate the role of these two genes as biomarkers during breast cancer diagnosis and screening.
Materials and methods: In this case- control study, we investigated the expression level of BRIP1 and PALB2 genes among 50 breast cancer patients in comparison with 50 control cases. Total RNA from blood samples were extracted and cDNA was synthesized. The specific primer for detection of gene markers was designed and expression level of BRIP1 and PALB2 in presence of GAPDH control gene was quantitatively studied by using qRT-PCR.
Results: The level of BRIP1 andPALB2 gene expression was significantly increased in breast cancer patients compared to control population. Results showed quantitative increase of BRIP1 and PALB2 genes with 3.419 and 7.326 fold respectively for breast cancer compared to normal samples (P=0.001). Also, the results were evaluated using the formulas 2-ΔΔCt according to the mean Ct of healthy subjects and grading of the disease showed a significant relationship with the expression of genes, so that by increasing staging and severity of cancer, the expression of biomarkers increased (p=0.003).
Conclusion: Based on significant increasing expression of PALB2 and BRIP1 genes in breast cancer patients in our study, probably increasing expression of these genes will inhibit the activity of tumor suppressor genes. So, we can introduce these genes as biomarker of breast cancer in the diagnostic work up of disease.
Keywords: BRIP1, PALB2, Real Time PCR, Marker
Full-Text [PDF 326 kb]   (2174 Downloads)    
Semi-pilot: Experimental | Subject: Genetic
Received: 2018/01/14 | Accepted: 2018/07/17 | Published: 2018/12/23
References
1. Giordano,A.and N. Normanno,Breast cancer in the post genomic era.2009: Springer Science & Business Media. [DOI:10.1007/978-1-60327-945-1]
2. Hosseinzadeh M, Eivazi Ziaei J, Mahdavi N, Aghajari P, Vahidi M, Fateh A. Risk factors for breast cancer in Iranian women :a hospital based case control study in Tabriz, Iran. J Breast Cancer 2014;17:236-243. [DOI:10.4048/jbc.2014.17.3.236]
3. Dumitrescu R, Cotarla I. Understanding breast cancer risk .Where do we stand in 2005. J Cell Mol Med 2005;9:208-221. [DOI:10.1111/j.1582-4934.2005.tb00350.x]
4. DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64:52-62. [DOI:10.3322/caac.21203]
5. Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: first results from a population-based cancer registry. East Mediterr Health J 2009;15:1426-31.
6. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374-403. [DOI:10.1016/j.ejca.2012.12.027]
7. Ebrahimi,M, M.Vahdaninia, A. Montazeri. Risk factors for breast cancer in Iran : a case control study. Breast Cancer Res 2002;4: r10. [DOI:10.1186/bcr454]
8. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive Biomarkers in oncology. Pre Med 2010;7:33-47. [DOI:10.2217/pme.09.49]
9. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26:1291-99. [DOI:10.1093/annonc/mdv022]
10. Simon R. Sensitivity. Specificity PPV and NPV for predictive biomarkers. J Natl Cancer Inst 2015;107: pii: djv153. [DOI:10.1093/jnci/djv153]
11. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin 2013;63:11-30. [DOI:10.3322/caac.21166]
12. Hayes DF. Biomarker Validation and testing .Molon col 2015;9:960-66. [DOI:10.1016/j.molonc.2014.10.004]
13. Xia B, Sheng Q, Nakanishi K. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol cell 2006;22:719-29. [DOI:10.1016/j.molcel.2006.05.022]
14. Zhang F, Ma J,Wu J. PALB2 links BRCA1 and BRCA2 in the DNA-damage response Curr Biol. 2009;19:524. [DOI:10.1016/j.cub.2009.02.018]
15. Casadei S, Norquist BM, Walsh T. Contribution of inherited mutations in the BRCA2 interacting protein PALB2 to familial breast cancer. Cancer Res. 2011; 71-2222-29.
16. Shirley M.H.SY. PALB2 is an integral component of the BRCA complex required for homologous recombination repair 5. Proc Natl Acad Sci U S A 2009; 106:7155-60. [DOI:10.1073/pnas.0811159106]
17. Bowman-Colin C, Xia B, Bunting S, Klijn C, Drost R, Bouwman P, et al. Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. Proc Natl Acad Sci U S A. 2013;110:8632-37. [DOI:10.1073/pnas.1305362110]
18. Monteiro LJ, Khongkow P, Kongsema M, Morris JR, Man C, Weekes D, et al. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment. Oncogene. 2013;32:4634-45. [DOI:10.1038/onc.2012.491]
19. Rohanizadegan M. Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. Cancer Genet. 2018 pii: S2210-7762:30292-2.
20. Loke SY, Lee ASG. The future of blood-based biomarkers for the early detection of breast cancer. Eur J Cancer. 2018;92:54-68. [DOI:10.1016/j.ejca.2017.12.025]
21. Sauter ER. Reliable Biomarkers to Identify New and Recurrent Cancer. Eur J Breast Health. 2017;13:162-167. [DOI:10.5152/ejbh.2017.3635]
22. Boschetti E, D'Amato A, Candiano G, Righetti PG. Protein biomarkers for early detection of diseases: The decisive contribution of combinatorial peptide ligand libraries. J Proteomics. 2017: S1874-3919:30285-3.
23. Bahrami A, Aledavood A, Anvari K, Hassanian SM, Maftouh M, Yaghobzade A, et al. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs. J Cell Physiol. 2018;233:774-786. [DOI:10.1002/jcp.25813]
24. Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction. Pharmacol Ther. 2017;172:34-49. [DOI:10.1016/j.pharmthera.2016.11.012]
25. Iranshahi N, Zafari P, Yari KH, Alizadeh E. The most common genes involved in epigenetics modifications among Iranian patients with breast cancer: A systematic review. Cell Mol Biol (Noisy-le-grand). 2016;31;62:116-122.
26. Mistry DA, French PW. Circulating Phospholipids as Biomarkers of Breast Cancer: A Review. Breast Cancer (Auckl). 2016;10:191-196. [DOI:10.4137/BCBCR.S40693]
27. Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, et al. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. J Clin Oncol. 2016;34:1455-59. [DOI:10.1200/JCO.2015.63.7454]
28. Zhao LL, Zhang T, Liu BR, Liu TF, Tao N, Zhuang LW. Construction of pancreatic cancer double-factor regulatory network based on chip data on the transcriptional level. Mol Biol Rep. 2014;41:2875-83. [DOI:10.1007/s11033-014-3143-4]
29. Raman D, Foo CH, Clement MV, Pervaiz S. Breast Cancer: A Molecular and Redox Snapshot. Antioxid Redox Signal. 2016;25:337-70. [DOI:10.1089/ars.2015.6546]
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Shafiee E, Hesampour A. Quantitative investigation of BRIP1 and PALB2 expression level in Iranian women with breast cancer compared to normal samples . MEDICAL SCIENCES 2018; 28 (4) :283-289
URL: http://tmuj.iautmu.ac.ir/article-1-1488-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 28, Issue 4 (winter 2018) Back to browse issues page
فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران Medical Science Journal of Islamic Azad Univesity - Tehran Medical Branch
Persian site map - English site map - Created in 0.05 seconds with 37 queries by YEKTAWEB 4645